"Good leaders blaze the way, making a PATH for all to follow..."
Together, our Leadership Team and Board of Directors focus our commitment to the essential values in leading the industry in innovation, addressing unmet medical needs and the customer experience.
CEO, President and Chairman of the Board
Anthony J. Dolisi
Anthony has built a 25+ year career in progressive leadership roles. He is a results-driven executive with a track record of success driving rapid revenue growth in start-up and/or turn around business environments. Extensive experience in pharmaceutical, biotech, and molecular diagnostics markets and medical devices, with first-in-class product launches in Cardiology, CNS, Oncology, Virology, Wound Care and Infectious Disease by leveraging best practices in clinical, sales, and commercial operations. Anthony has developed peak-performing commercial teams that consistently maximize productivity and revenue generation. His experience is both broad and deep and includes: Launch Planning, P&L Management, Licensing & Co-Promotion, Team Leadership & Motivation, Brand/Consumer Marketing, Med-ED/KOL Development, Creative Market Segmentation, Managed Care/Contracting, Community/Patient Advocacy. His industry experience specializes in business leadership with fortune 500 companies including American Home Products, Glaxo SmithKline, Agouron, Pfizer, and Johnson & Johnson. Combining both commercial and clinical expertise, he has made his mark by building multi-million-dollar businesses, igniting growth in business lines, devising innovative differentiated product strategies, and spurring company growth through creative and comprehensive portfolio strategies. As President & CEO, Anthony is responsible for all the functional sectors of the Olaregen organization, driving the performance and success of the business. Anthony will lead in the efforts to commercialize products, overseeing all facets of the company’s go-to-market strategy as well as playing a vigorous role in pipeline development, acquisitions, and strategic alliances.
Chief, Medical & Legal Affairs
Frank Dolisi, MD, JD
Frank joins Olaregen as an experienced surgeon with credentials in research and health law as the Chief of Medical and Legal Affairs. He graduated from the Jesuit Fordham University before attending medical school in Syracuse N.Y. , Frank pursued a career in Ob/Gyn at currently NYU- Winthrop University Hospital on Long Island NY. A strong interest in learning and a passion to help others encouraged Frank to pursue a second doctoral degree in Law at Hofstra University School of Law, concentrating and receiving awards in Health Law. , Frank moved forward by orchestrating a multimillion dollar physician group merger becoming Women’ Health Professionals LLP. Leading Women’s Health Professionals as a Board member, Vice- President, Medical Director, and currently Chief Compliance Officer, Dr. Dolisi became a catalyst in bringing his medical group to partner with the U.S. Women’s Health Alliance. The USWHA is a large private Ob/Gyn partnership that boasts over 3,000 members in 30 states caring for over 10 million women and dedicated to improving women’s health in the U.S. and elsewhere. Dr. Dolisi assumed a leadership role as a member of the board of directors and created and chaired the research committee of the USWHA. The committee has launched a nation-wide effort to perform clinical research in women’s health to expedite bringing new products and devices to market to better serve women.
Chief Operating Officer, EVP Commercial Operations
Cliff has a demonstrated 25-years of leadership success in the Life Sciences sector and is currently the Chief Operating Officer, Executive Vice President of Commercial Operations at Olaregen Therapeutix Inc. He has a proven track record of developing high performance “A” teams, driving revenue, exceeding goals, developing markets and launching new products and services. Cliff has held various senior leadership positions with privately held and publicly traded Fortune 500 companies, including start- ups and established organizations. His bio-pharmaceutical career included positions at Astra USA, Dupont Pharmaceuticals and Gilead Sciences. Additional career experience includes the Direct-to-Patient wound care sector, serving as a Regional Operations Director for Restorix Health Services and in the specialty pharmacy market with Meijer Specialty Pharmacy. He has served as a consultant in the life sciences sector for investment banks, evaluating the potential viability of start-up life sciences companies in various therapeutic areas and service related offerings. Cliff will be responsible for all related commercial operations of the company, including the sales and marketing functions. His primary responsibility will be to deliver profitability for the greater organization, as well as the successful execution of new launches and change initiatives.ion of new launches and change initiatives.
Scientific Consultant, Inventor of Excellagen®
Lois Chandler, PhD,
Lois received her PhD in Biochemistry from the University of Southern California and was a Post-Doctoral Fellow at the Salk Institute for Biological Studies. She is currently Vice President of Product Development for Angionetics Inc. (subsidiary of Gene Biotherapeutics Inc.). Lois was responsible for Chemistry, Manufacturing, and Controls and Quality Control activities and regulatory submissions resulting in FDA 510(k)-clearance of Excellagen® and clinical advancement of gene therapy product candidates for dermal wound healing and therapeutic angiogenesis. Lois established and implemented Gene Biotherapeutics’ Quality Management Systems, which resulted in successful ISO 13485 Certification. In the process, she fostered mutually respectful alliances with Contract Manufacturers and Contract Testing organizations, and worked through technical challenges, achieving validated procedures, and outcomes meeting budget, timeline, and material supply requirements. Lois will be responsible for technical/scientific matters as it relates to the developmental process that created Excellagen. She will also provide guidance on the various stages of production of Excellagen. Lois was awarded the Patent for Excellagen in June 2018. She currently heads R&D at Angionetics and leads the team creating the first gene-based therapy for refractory angina.
Chief Operating Officer
The distributions, accounting and tax services for Olaregen will be handled by PPMT Strategic Group, a subsidiary of PPMI (which is a fully reporting public company) that has provided the delivery of the following business services to third party clients since 2009: CFO Services, Accounting and Tax Services, Insurance and Healthcare Insurance Services
PPMT Strategic Group will thus provide monthly accounting, payroll, tax, billing and financial services while also maintaining the books to provide complete financial transparency through regular minimum quarterly reporting. PPMT Strategic Group is a contractor that has been retained by Olaregen to perform the above services.
Sr. VP of Sales and Business Development
Scott has an accomplished history of success with over a 20 year career having served in numerous leadership roles across a variety therapeutic areas, including neurology, rare disease, asthma, and diabetes. Scott has held various strategic and operational roles with full P&L responsibility in both established and newly formed companies. He has broad expertise in building, leading and motivating teams through fostering a culture of collaboration and innovation.
Having served previously as the chief architect of several successful newly-formed biotech organizations, Scott will be spearheading the commercial performance of all Olaregen marketed brands. He will be responsible for creating an engine of innovation to identify and develop new and strategically aligned commercial opportunities to drive Olaregen’s growth.
Scott joined Olaregen after serving as the Chief Commercial Officer Vyera Pharmaceuticals where he optimized the commercial organization, launched new products and drove the growth of the specialty care portfolio. His responsibilities included, market access, patient support, specialty pharmacy, distribution sales and marketing. His previous role at Shire was as the Sr. Area Sales Director and Sr. Marketing Director for the CNS franchise. His breadth and depth of experience have provided Scott with adaptability to be nimble required for leaders in the new and fast paced biotech industry.
Vice President of Business Strategy
John will lead and coordinate the activities and operations of the Business Strategy team responsible for executing all aspects of the organization’s overall business strategy, sales and market planning, and financial forecasts.
He has over 30 years of experience in commercial, marketing, and strategic planning roles within the medical device industry, primarily in the wound care field. He joins Olaregen from Integra Life Sciences where he was Senior Director of Global Marketing for Regenerative Technologies, overseeing brand marketing of the company’s soft tissue repair portfolio. Prior to Integra, Mr. Sentman held various sales, management, and marketing roles, both domestically and internationally over a 20-year career with ConvaTec, a leading manufacturer of wound care products. Mr. Sentman received his bachelor’s degree in finance from American University’s School of Business.
Board Of Directors
Our advisors are a group of highly experienced professionals that provide non-binding strategic advice to the management of our corporation. The nature of our advisory board gives greater flexibility in structure and management compared to the board of directors.